Loading company
BioLineRx Ltd.
BLRX · Nasdaq · ·
$2.60+3.2%Sep 25 close
- 1M
- 0.0%
- 6M
- +15.6%
- 1Y
- -31.2%
- 5Y
- -97.7%
BLRX · Nasdaq · ·
$2.60+3.2%Sep 25 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $294K | $255K | +15.29% |
| Profit | -$3.9M | -$6.8M | +42.41% |
| Profit per share | $0.00 | -$6.00 | +100.00% |
| Free Cash Flow | -$2.3M | -$8M | +71.60% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
BioLineRx Ltd. has no earnings call transcript available.
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company’s lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS. The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University. Learn more about who we are, what we do, and how we do it at www.biolinerx.com , or on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K BioLineRx Ltd. filed on August 31, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.